Ensysce Biosciences, Inc. stock is down -7.61% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 December’s closed higher than November.
Ensysce Biosciences, Inc. engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended. release prodrugs of amphetamine for ADHD medication abuse.